Macitentan (Opsumit) is a novel oral dual endothelin receptor antagonist for pulmonary hypertension. Actelion submitted its FDA new drug application for macitentan in October 2012.
Endothelial to Mesenchymal Transition (EndMT): Role in Physiology and in the Pathogenesis of Human Diseases. The identification of molecules and regulatory pathways involved in EndMT and the discovery of specific EndMT inhibitors should provide novel therapeutic approaches for various human disorders mediated by EndMT. PubMed, Physiol Rev, 2019 Apr 1;99(2):1281-1324. (Also see Tracleer (Bosentan) and Fibroblasts)
(Update) Sara P: CREST Syndrome I am still doing well. Iíve been stable on the PAH meds, Opsumit and ADCIRCA.
(Update) Sherri M: CREST Syndrome. I have been put on Opsumit for the Pulmonary Hypertension. I have been on it for ten weeks now. I started to notice a tiny difference at around week 7; I felt just a little less short of breath.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: